The drug, called Perjeta combines Roche’s Herceptin drug along with chemotherapy. It works by targeting a different part of the HER-protein than Herceptin does. This resulted in a further reduction in growth of the HER2-positive breast cancer cells and prevents them from surviving.
Approval from the FDA came as a result of a successful Phase III study which found that patients who took a combination of Perjeta, Herceptin and docetaxel lived 6.1 months longer without their cancer getting worse.
Speaking of the FDA approval, Chief Medical Officer and Head of Global Product Development at Roche, Hall Barron, stated, “Today’s approval of Perjeta is an important advance in the treatment of HER2-positive
metastatic breast cancer. Perjeta attacks HER2-positive tumours differently than Herceptin. Based on the way the two medicines work together, the combination plus chemotherapy can prolong the time before this aggressive cancer worsens compared to Herceptin and chemotherapy alone. We are very pleased to see our efforts in studying the science of HER2 translate into another personalized medicine.”